Investment Summary |
|
|---|---|
| Date | 2025-11-05 |
| Target | Evommune |
| Sector | Life Science |
| Sellers(s) |
Andera Partners
EQT Life Sciences |
| Deal Type | IPO |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 52 of 52 |
| Sector: Life Science M&A | 10 of 10 |
| Type: IPO M&A Deals | 7 of 7 |
| State: California M&A | 3 of 3 |
| Country: United States M&A | 4 of 4 |
| Year: 2025 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-23 |
Adler Ortho
Cormano, Italy Adler Ortho designs, produces, and distributes orthopedic implants, surgical instruments, and bioresorbable products, with emphasis on 3D-printed complex applications. The company serves international markets across multiple orthopedic specialties. Adler Ortho was founded in 2004 and is based in Cormano, Italy. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1987 |
| PE ASSETS | 3.5B EUR |
| Size | Large |
| Type | Sector Focused |
EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 10 |
| Sector: Life Science M&A | 6 of 6 |
| Type: IPO M&A Deals | 2 of 2 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 4 of 4 |
| Year: 2025 M&A | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-22 |
Imcheck Therapeutics
Marseilles, France ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France. |
Sell | - |
